Navigation Links
Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments
Date:3/19/2019

Sheba Medical Center at Tel HaShomer, the largest hospital in Israel and the Middle East region, and Swiss-based CDMO Lonza announced a collaboration to develop point-of-care cell-therapy manufacturing using the state-of-the-art Cocoon™ manufacturing platform. The partnership will enable Sheba to vastly streamline its in-house cell manufacturing process and produce genetically engineered human CAR-T cells for applications in treating critically ill oncology patients.

This collaborative agreement brings together a leading academic clinical center and an established development and manufacturing partner with the goal of delivering potentially curative therapies to a greater number of patients with advanced hematological malignancies. Sheba Medical Center has a proven track record of treating oncology patients using novel immunotherapy treatments such as CAR-T. Lonza will leverage its expertise in autologous cell-therapy process development to transfer Sheba’s current open, manual protocols into Lonza’s closed, automated Cocoon™ platform.

"With the collaborative potential of this venture, we look forward to jointly leading the next personalized cell-therapy revolution. Lonza’s Cocoon™ platform provides us the ability to manufacture cell therapies faster and closer to the point-of-care and in a scalable manner at lower cost so that we can treat more oncology patients who turn to us as a last resort," said Professor Dror Harats, MD, Deputy Director for Research and Development and Director for Clinical Trials at Sheba Medical Center.

Eytan Abraham, Head of Personalized Medicine, Lonza Pharma Biotech & Nutrition added, “This collaboration with Sheba Medical Center, a proven leader in point-of-care manufacturing and treatment of patients with novel immunotherapies, is a key part of the development program for the Cocoon™ platform. We aim to confirm the benefits of using our closed, automated GMP-in-a-box concept to more efficiently manufacture personalized cell therapies right where the patients are, enabling treatment of a larger patient population.”

About the Cocoon™ Technology
The Cocoon™ system is a patient-scale closed, automated cell therapy manufacturing system. Designed with customizable, disposable cassettes to accommodate a wide range of autologous cell therapy processes, the Cocoon™ system incorporates the majority of unit operations needed for scalable end-to-end cell therapy manufacturing for uses in immunotherapy (i.e. CAR-T) and regenerative medicine (i.e. MSCs).By automating autologous cell therapy manufacturing in a closed automated system, the Cocoon™ platform enables superior process control leading to fewer deviations along with increased cell quality and yield. The Cocoon™ device is currently in Beta-testing with a selection of cell and gene therapy customers.

About Sheba Medical Center…
The Sheba Medical Center at Tel HaShomer is a university-affiliated tertiary referral hospital that serves as Israel's national medical center in many fields.
Adjacent to Tel Aviv, it is the most comprehensive medical center in the Middle East, renowned for its compassionate care and leading-edge medicine. It is also a major medical-scientific research powerhouse that collaborates internationally with the bio-tech and pharmaceutical industries to develop new drugs, treatments and technologies, and a foremost global center for medical education.

https://eng.sheba.co.il/

About Lonza
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma Biotech & Nutrition segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers' preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at http://www.lonza.com

PRESS INTERVIEWS ARE AVAILABLE WITH PROF. HARATS & EYTAN ABRAHAM…
For more information, contact Jodie Singer, Sr. Account Executive
Red Banyan
E-mail: Jodie(at)Redbanyan.com
Tel: 202-597-5477

Sanna Fowler, Head of Public Relations
Lonza Pharma Biotech & Nutrition
Tel +41 61 316 8929
sanna.fowler(at)lonza.com

Read the full story at https://www.prweb.com/releases/sheba_medical_center_to_collaborate_with_lonza_pharma_on_state_of_the_art_cocoon_platform_to_aid_cancer_patients_access_to_life_saving_car_t_immunotherapy_treatments/prweb16178108.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
2. Astute Medical, Inc. ospiterà il simposio sullinsufficienza renale al 33o incontro annuale ISICEM
3. Astute Medical, Inc. organizará el 33. simposio anual en el congreso ISICEM sobre daño renal
4. Astute Medical, INC. ist Veranstalter eines SYMPOSIUMS zu Nierenerkrankungen beim 33. jährlichen ISICEM
5. Astute Medical, Inc. va Accueillir le Symposium portant sur linsuffisance rénale du 33e ISICEM annuel
6. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
7. Medical Gases and Equipment Market is Expected to Reach USD 9 Billion Globally in 2018: Transparency Market Research
8. Clinical Trials and Medical Research in Texas Create Jobs and Save Lives
9. Cellular Dynamics and Coriell Institute for Medical Research Awarded Multi-Million Dollar Grants from California Institute for Regenerative Medicine to Manufacture and Bank Stem Cell Lines
10. Final Week of IpAuctions, Inc. All Things Medical Auction Event
11. Medical University of South Carolina Selects Elseviers Interdisciplinary Care Planning and Clinical Documentation Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2019)... Utah and BOSTON (PRWEB) , ... April 08, ... ... delivering cloud-based enterprise-class unified communications and collaboration solutions, announced today the launch of ... integration to an unprecedented range of business and contact-orientated applications while using CT ...
(Date:4/8/2019)... (PRWEB) , ... April 09, 2019 , ... ... disease, the innovative non-profit research center Chan Zuckerberg Biohub (CZ Biohub) has chosen ... of antibody repertoires is part of CZ Biohub’s efforts to establish new approaches ...
(Date:4/4/2019)... (PRWEB) , ... April 03, 2019 , ... ... together through intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference ... offers insights into the industry’s challenges and opportunities with high-level panels and discussions ...
(Date:3/27/2019)... ... ... A leader in the field of Regenerative Veterinary Medicine, VetStem Biopharma has ... Canada since 2004. The primary indications for VetStem Regenerative Cell Therapy are ... and horse. Recently, VetStem teamed up with the world-renowned San Diego Zoo to ...
Breaking Biology Technology:
(Date:4/4/2019)... ... April 02, 2019 , ... Researchers from Ambry Genetics ... RNA genetic testing (RGT), as a supplement to DNA genetic testing, improves variant ... poster, is one of 13 presentations at the 2019 American College of Medical ...
(Date:4/1/2019)... ... April 01, 2019 , ... ... Characterizing Skin Related Conditions” by the US Patent and Trademark Office on January ... an invention by uBiome collaborators Dr. Zachary Apte, Dr. Daniel Almonacid, Dr. ...
(Date:3/29/2019)... ... ... In the development of biosimilars, the broad definition of the similarity concept in ... several manufacturers have been successful and numerous follow-on biologics are approved in the US ... analytical similarity is achieved in biosimilars based on recently approved products in the US. ...
Breaking Biology News(10 mins):